Date: 2012-11-22
Type of information: R&D agreement
Compound: TIQUAS (Targeted In-depth QUAntification of cell Signaling) phosphoproteomics platform
Company: Activiomics (UK) Kyowa Hakko Kirin (Japan)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: Activiomics has signed a research agreement with Kyowa Hakko Kirin. Under the agreement, Activiomics will apply its novel TIQUAS phosphoproteomics platform to elucidate signalling mechanisms of lead compounds in relevant cell-based systems. This agreement was signed as part of Activiomics’ recently announced strategic partnership with BioFocus.
Financial terms:
Latest news:
